Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Appointment #CSEStocks #OTC #OTCMarkets #OTCStocks #SmallCaps #Investing
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.Dr. Beaver has held senior leadership positions at several... http://dlvr.it/TSrffG